# Immunotherapy In Locally Advanced Rectal Cancer

> **NCT03854799** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 101 (actual)

## Conditions studied

- Colon Rectal Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Capecitabine
- **RADIATION:** EXTERNAL---BEAM IRRADIATION 50.4 GY

## Key facts

- **NCT ID:** NCT03854799
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2021-02-15
- **Final completion:** 2023-09-30
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854799, "Immunotherapy In Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03854799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*